10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

Rhea-AI Summary

10x Genomics (NASDAQ: TXG) announced a multi-year collaboration with Dana-Farber Cancer Institute to analyze tumor samples from hundreds of patients across major solid tumor types using single cell and spatial profiling. The initiative aims to identify biomarkers tied to treatment response, resistance and progression and to define a clinical reporting framework to support precision oncology. 10x also plans to establish a CLIA-certified laboratory to enable assay implementation, analytical validation and future diagnostic services using its Chromium Flex single cell assay and Xenium spatial platform.

Positive

• Study will analyze tumor samples from hundreds of patients
• Plans to establish a CLIA-certified laboratory for assay validation
• Use of Chromium Flex and Xenium platforms for integrated profiling
• Collaboration targets biomarkers for multiple emerging oncology therapies

Negative

• No validated clinical diagnostic test ready; efforts described as research and planning
• Outcomes and clinical utility depend on multi-year research and future validation

News Market Reaction – TXG

-3.23%

34 alerts

-3.23% News Effect

-4.3% Trough in 25 min

-$82M Valuation Impact

$2.45B Market Cap

0.6x Rel. Volume

On the day this news was published, TXG declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $82M from the company's valuation, bringing the market cap to $2.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $22.13 Vol: Volume 3,870,770 vs 20-da...

high vol

$22.13 Last Close

Volume Volume 3,870,770 vs 20-day avg 2,231,508 (1.73x), indicating elevated trading interest. high

Technical Price 20.46 sits near 52-week high 20.72 and above 200-day MA 12.59.

Peers on Argus

TXG gained 6.07% while peers were mixed: CERT -4.31%, SDGR -2.34%, OMCL +1.06%, ...

TXG gained 6.07% while peers were mixed: CERT -4.31%, SDGR -2.34%, OMCL +1.06%, PHR +0.47%, GDRX +0.72%, pointing to a stock-specific move.

Historical Context

5 past events · Latest: Dec 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 29	Conference participation	Positive	+0.9%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast access.
Nov 18	Research consortium	Positive	-0.9%	Launch of ASTRA consortium using Xenium to build pan-cancer spatial atlas.
Nov 11	Conference participation	Positive	+0.6%	Participation in Wolfe Research Healthcare Conference fireside chat and webcast.
Nov 06	Quarterly earnings	Neutral	-3.6%	Q3 2025 earnings with $149M revenue, 67% margin, narrowed losses and Q4 guidance.
Oct 29	Product launch	Positive	-3.3%	Launch of next-gen Chromium Flex assay to scale single cell studies globally.

Pattern Detected

Recent collaboration and product news (e.g., Chromium Flex launch, ASTRA consortium) showed mixed price reactions, while conference appearances had modest positive moves. Earnings drew a modest negative reaction.

Recent Company History

Over the past few months, 10x Genomics reported Q3 2025 results with revenue of $149.0M and a 67% gross margin, alongside narrowed operating and net losses. The company launched the next generation Chromium Flex assay to scale single cell research and joined the ASTRA consortium to build a pan-cancer spatial atlas. It also participated in major healthcare conferences. Today’s Dana-Farber collaboration and planned CLIA lab extend this strategy toward clinical and diagnostic applications.

Market Pulse Summary

This announcement extends 10x Genomics’ move from research tools toward clinical applications by pai...

Analysis

This announcement extends 10x Genomics’ move from research tools toward clinical applications by pairing single cell and spatial profiling with Dana-Farber’s oncology expertise. The multi-year effort, using platforms such as Chromium Flex and Xenium, targets biomarkers and treatment-response signatures and is supported by a planned CLIA lab for assay validation and processing. Investors may track future updates on clinical reporting frameworks, additional collaborators, and how these efforts connect to revenue trends and prior product launches.

Key Terms

biomarkers, precision oncology, antibody-drug conjugates, radioligand therapies, +4 more

8 terms

biomarkers medical

"aims to identify biomarkers linked to treatment response for the next"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

precision oncology medical

"framework to power precision oncology10x also plans to establish a"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

antibody-drug conjugates medical

"including antibody-drug conjugates (ADCs), radioligand therapies (RLTs),"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

radioligand therapies medical

"antibody-drug conjugates (ADCs), radioligand therapies (RLTs), bispecific"

Radioligand therapies are treatments that combine a molecule that seeks out specific disease cells with a small radioactive particle, delivering radiation directly to those cells much like a guided missile delivers a warhead to a target. They matter to investors because successful therapies can create new, high-value products and revenue streams while also carrying clinical, regulatory and manufacturing risks that can dramatically affect a company’s valuation and future prospects.

bispecific antibodies medical

"radioligand therapies (RLTs), bispecific antibodies, immune checkpoint"

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

immune checkpoint inhibitors medical

"bispecific antibodies, immune checkpoint inhibitors and other precision"

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

tumor microenvironment medical

"evaluate therapeutic targets and relevant tumor microenvironment features"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

clia-certified laboratory regulatory

"10x also plans to establish a CLIA-certified laboratory to enable"

A CLIA-certified laboratory is a medical testing lab that meets U.S. federal standards for accuracy, reliability and quality control when performing human diagnostic tests. Think of it like a safety inspection or driver's license for labs: certification shows tests are run under approved procedures and oversight. For investors, CLIA certification reduces regulatory and operational risk, affects a lab’s ability to bill insurers and sell diagnostic services, and can influence revenue and growth potential.

AI-generated analysis. Not financial advice.

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology

10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests

PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.

The study with Dana-Farber intends to examine samples from hundreds of patients to evaluate therapeutic targets and relevant tumor microenvironment features for the most promising emerging therapies in oncology, including antibody-drug conjugates (ADCs), radioligand therapies (RLTs), bispecific antibodies, immune checkpoint inhibitors and other precision approaches. These treatments are reshaping the standard of care, yet patients can experience dramatically different outcomes. By understanding why patients respond differently to the same treatments, this research initiative may eventually help clinicians optimize therapy accordingly and move beyond current assays to capture the cellular ecosystems, immune activity and spatial context that influence how tumors respond to treatment.

Using 10x's Chromium Flex single cell assay and Xenium spatial platform, the investigators will generate molecularly detailed maps of tumors that integrate both cellular composition and spatial architecture. By pairing these profiles with known clinical outcomes, the collaboration aims to reveal the biological features that distinguish patients who benefit from treatment from those who do not. Additionally, 10x and Dana-Farber will collaborate in defining actionable biomarkers for future clinical reporting, exploring how spatial and single cell insights, such as target expression patterns, immune contexture or indicators of therapeutic sensitivity, could be summarized in a format designed to support oncologists as they navigate increasingly complex treatment decisions.

"Collaborations like this are important for advancing precision oncology," said Himisha Beltran, MD, Director of Translational Research in Medical Oncology at Dana-Farber. "Integrating high-resolution tumor profiling with clinical outcomes allows us to study treatment response and resistance across solid tumors, generating insights that can inform future clinical applications."

In parallel with this scientific collaboration, 10x's planned CLIA laboratory build-out will provide the regulated infrastructure needed for assay implementation, analytical validation and clinical sample processing, and also create the critical infrastructure necessary to deploy innovative diagnostic services for future clinical use.

"Through partnerships announced in 2025, we've already seen how single cell and spatial profiling can impact translational research, and we believe this is only the beginning," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Our goal is to accelerate the arrival of a world where deep, multidimensional biology directly informs patient care. That means continuing to empower our customers in their research, while also engaging in clinical collaborations like the one with Dana-Farber that help us advance how these insights translate into improved outcomes for patients. Establishing a CLIA lab is a natural next step for 10x and will strengthen the support we provide to investigators in academia and biopharma as they design, validate and bring forward the next generation of precision medicines."

This collaboration marks the beginning of a multi-year research effort through which 10x will collaborate with leading institutions to generate the scientific evidence needed to develop the clinical potential of single cell and spatial technologies. Additional studies and collaborations are planned, each contributing to the foundational work required to develop potential clinical tests in the future.

About 10x Genomics
10x Genomics is a life science technology company building research products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in the United States and/or certain other countries.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-advance-research-in-diagnostic-applications-of-tumor-single-cell-and-spatial-profiling-302657873.html

SOURCE 10x Genomics, Inc.

FAQ

What is the goal of 10x Genomics' collaboration with Dana-Farber (TXG) announced January 12, 2026?

The collaboration aims to identify biomarkers linked to treatment response, resistance and progression to inform potential diagnostic workflows.

How many patient samples will 10x Genomics and Dana-Farber analyze in the TXG study?

The study intends to examine samples from hundreds of patients across major solid tumor types.

What technologies will 10x Genomics use in the tumor profiling collaboration (TXG)?

The company will use the Chromium Flex single cell assay and the Xenium spatial platform to generate integrated molecular maps.

Why is 10x Genomics planning a CLIA-certified laboratory (TXG)?

The CLIA lab is intended to provide regulated infrastructure for assay implementation, analytical validation and clinical sample processing for future diagnostic services.

Which types of therapies will the TXG–Dana-Farber study investigate for biomarker associations?

The study will evaluate emerging therapies including ADCs, radioligand therapies, bispecific antibodies, immune checkpoint inhibitors and other precision approaches.

Does the January 12, 2026 TXG announcement deliver an immediate clinical test for patients?

No; the announcement describes research and plans for future diagnostic development, not an immediately available clinical test.